Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.ppat.1009225 http://scihub22266oqcxt.onion/10.1371/journal.ppat.1009225 33596266!7888651!33596266     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       PLoS+Pathog 2021 ; 17 (2): e1009225 Nephropedia Template TP {{tp|p=33596266|t=2021. SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development |pdf=|usr=}}{{33596266}} gab.com Text SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development JO: PLoS Pathog http://www.kidney.de/pget.php?&tw=1&pmid=33596266 #FOAvip Since the initial report of the novel Coronavirus Disease 2019 (COVID-19) emanating from Wuhan, China, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread globally. While the effects of SARS-CoV-2 infection are not completely understood, there appears to be a wide spectrum of disease ranging from mild symptoms to severe respiratory distress, hospitalization, and mortality. There are no Food and Drug Administration (FDA)-approved treatments for COVID-19 aside from remdesivir; early efforts to identify efficacious therapeutics for COVID-19 have mainly focused on drug repurposing screens to identify compounds with antiviral activity against SARS-CoV-2 in cellular infection systems. These screens have yielded intriguing hits, but the use of nonhuman immortalized cell lines derived from non-pulmonary or gastrointestinal origins poses any number of questions in predicting the physiological and pathological relevance of these potential interventions. While our knowledge of this novel virus continues to evolve, our current understanding of the key molecular and cellular interactions involved in SARS-CoV-2 infection is discussed in order to provide a framework for developing the most appropriate in vitro toolbox to support current and future drug discovery efforts. Twit Text FOAVip SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development ????PLoS Pathog http://www.kidney.de/pget.php?&tw=1&pmid=33596266 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33596266 #FOAvip English Wikipedia <ref>{{Cite pmid|33596266}}</ref> SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development #MMPMID33596266 Murgolo N; Therien AG; Howell B; Klein D; Koeplinger K; Lieberman LA; Adam GC; Flynn J; McKenna P; Swaminathan G; Hazuda DJ; Olsen DB PLoS Pathog 2021[Feb]; 17 (2): e1009225 PMID33596266show ga Since the initial report of the novel Coronavirus Disease 2019 (COVID-19) emanating from Wuhan, China, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread globally. While the effects of SARS-CoV-2 infection are not completely understood, there appears to be a wide spectrum of disease ranging from mild symptoms to severe respiratory distress, hospitalization, and mortality. There are no Food and Drug Administration (FDA)-approved treatments for COVID-19 aside from remdesivir; early efforts to identify efficacious therapeutics for COVID-19 have mainly focused on drug repurposing screens to identify compounds with antiviral activity against SARS-CoV-2 in cellular infection systems. These screens have yielded intriguing hits, but the use of nonhuman immortalized cell lines derived from non-pulmonary or gastrointestinal origins poses any number of questions in predicting the physiological and pathological relevance of these potential interventions. While our knowledge of this novel virus continues to evolve, our current understanding of the key molecular and cellular interactions involved in SARS-CoV-2 infection is discussed in order to provide a framework for developing the most appropriate in vitro toolbox to support current and future drug discovery efforts. |*Drug Discovery[MESH] |*Viral Tropism[MESH] |*Virus Internalization[MESH] |*Virus Replication[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/virology[MESH] |Cathepsins[MESH] |Cell Line[MESH] |Drug Development[MESH] |Endocytosis[MESH] |Furin[MESH] |Humans[MESH] |SARS-CoV-2/drug effects/*physiology[MESH]SARS-CoV-2 tropism, entry, replication, and propagation: Consideration(epmc).pdf DeepDyve Pubget Overpricing